Improving drug delivery to the brain after a stroke using targeted nanomedicine
Targeting the gatekeepers: Bolstering blood-brain barrier function using targeted nanomedicine in acute ischemic stroke
This study is exploring a new way to deliver medicine directly to the damaged parts of the brain during a stroke, using tiny carriers that can find and target those areas, which could make treatments more effective for people experiencing an acute ischemic stroke.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11103390 on NIH RePORTER |
What this research studies
This research focuses on enhancing the delivery of medications to the brain during acute ischemic stroke by using targeted nanomedicine. The approach involves creating nanocarriers that specifically target the damaged areas of the brain, allowing for a higher concentration of therapeutic agents where they are most needed. By utilizing a specific molecule that is overexpressed in the injured brain tissue, the researchers aim to significantly improve the effectiveness of treatments. The study will involve animal models to test the safety and efficacy of these targeted therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced an acute ischemic stroke and are within the appropriate time frame for treatment.
Not a fit: Patients who have not experienced an acute ischemic stroke or those with chronic neurological conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from acute ischemic stroke, potentially improving recovery outcomes and survival rates.
How similar studies have performed: Previous studies have shown promising results with targeted drug delivery approaches in animal models, indicating potential for success in this novel application.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Marcos-Contreras, Oscar a. — University of Pennsylvania
- Study coordinator: Marcos-Contreras, Oscar a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.